Pharmacological Inhibitors of the Mitogen-activated Protein Kinase (MAPK) Kinase/MAPK Cascade Interact Synergistically with UCN-01 to Induce Mitochondrial Dysfunction and Apoptosis in Human Leukemia Cells

Yun Dai, Chunrong Yu, Victor Singh, Lin Tang, Zhiliang Wang, Robert McInistry, Paul Dent, and Steven Grant

Division of Hematology/Oncology [Y. D., C. Y., V. S., Z. W., S. G.], Departments of Pharmacology [S. G.], Biochemistry [S. G.], Microbiology [L. T., S. G.], and Radiation Oncology [R. M., P. D.], Medical College of Virginia, Richmond, Virginia 23298

ABSTRACT

Interactions between the checkpoint abrogator UCN-01 and several pharmacological inhibitors of the mitogen-activated protein kinase (MAPK) kinase (MEK)/MAPK pathway have been examined in a variety of human leukemia cell lines. Exposure of U937 monocytic leukemia cells to a marginally toxic concentration of UCN-01 (e.g., 150 nM) for 18 h resulted in phosphorylation/activation of p42/44 MAPK. Coadministration of the MEK inhibitor PD184352 (10 μM) blocked UCN-01-induced MAPK activation and was accompanied by marked mitochondrial damage, e.g., cytochrome c release and loss of ΔΨm, caspase activation, DNA fragmentation, and apoptosis. Similar interactions were noted in the case of other MEK inhibitors (e.g., PD98059; U0126) as well as in multiple other leukemia cell types (e.g., HL-60, Jurkat, CCRF-CEM, and Raji). Coadministration of PD184352 and UCN-01 resulted in reduced binding of the cdc25C phosphatase to 14-3-3 proteins, enhanced dephosphorylation/activation of p34cdc2, and diminished phosphorylation of cyclic AMP-responsive element binding protein. The ability of UCN-01, when combined with PD184352, to antagonize cdc25C/14-3-3 protein binding, promote dephosphorylation of p34cdc2, and potentiate apoptosis was mimicked by the ataxia telangectasia mutation inhibitor caffeine. In contrast, SB203580, which inhibits multiple kinases including p38 MAPK, partially antagonized cell death. Lastly, although UCN-01, when combined with PD184352, to antagonize cdc25C/14-3-3 protein binding, promote dephosphorylation of p34cdc2, and potentiate apoptosis was mimicked by the ataxia telangectasia mutation inhibitor caffeine. In contrast, SB203580, which inhibits multiple kinases including p38 MAPK, partially antagonized cell death. Lastly, although UCN-01 ± PD184352 did not induce p21CIP1, stable expression of a p21CIP1 antisense construct significantly increased susceptibility to this drug combination. Together, these findings indicate that exposure of leukemic cells to UCN-01 leads to activation of the MAPK cascade and that interruption of this process by MEK inhibition triggers perturbations in several signaling and cell cycle regulatory pathways that culminate in mitochondrial injury, caspase activation, and apoptosis. They also raise the possibility that disrupting multiple signaling pathways, e.g., by combining UCN-01 with MEK inhibitors, may represent a novel antileukemic strategy.

INTRODUCTION

UCN-01 (7-hydroxystaurosporine) is a derivative of staurosporine that was originally developed as an inhibitor of PKC (1). However, UCN-01 has since been shown to inhibit other kinases, including Chk1, which is responsible for phosphorylation, binding to 14-3-3 proteins, and subsequent degradation of the cdc25c phosphatase (2). Degradation of cdc25c results in phosphorylation and inactivation of CDKs such as CDK1 (p34cdc2), which are critically involved in cell cycle arrest after DNA damage and other insults (3). In this way, UCN-01 acts as a checkpoint abrogator, an action that may account for its ability to enhance the lethal actions of various cytotoxic agents, including cisplatin (4), mitomycin C (5), camptothecin (6), fludarabine (7), gemcitabine (8), and 1-β-D-arabinofuranosylcytosine (9, 10), among others. When administered alone, UCN-01 induces arrest in G2-M or G0-G1, depending upon cell type, or, alternatively, the p53 or pRb status of the cell (11, 12). UCN-01 is also a potent inducer of apoptosis, particularly in hematopoietic cells, a phenomenon that appears to be more closely related to dephosphorylation of CDKs than to inhibition of PKC (13).

Phase I and pharmacokinetic studies of UCN-01 have been initiated in humans and have shown that this compound exhibits a very long plasma half-life, presumably a consequence of extensive binding to α1 acidic glycoprotein (14). Nevertheless, free plasma levels of UCN-01 capable of inhibiting Chk 1 and abrogating checkpoint control events appear to be achievable (15, 16). In a preliminary study (16), combination of UCN-01 with established cytotoxic agents was associated with evidence of clinical activity in a patient with advanced non-Hodgkin’s lymphoma, raising the possibility that UCN-01 may enhance the in vivo activity of conventional chemotherapeutic drugs.

Despite the intense interest in UCN-01 as an antineoplastic agent, the mechanism(s) by which it induces cell death remain(s) incompletely understood. Recently, considerable attention has focused on the role of signal transduction pathways in the regulation of cell survival, particularly those related to three parallel MAPK modules. Of these, the SAPK/JNK and p38 kinase are primarily induced by environmental insults (e.g., DNA damage or osmotic stress) and are generally associated with pro-apoptotic actions (17, 18). In contrast, p42/44 MAPKs (ERKs) are induced by mitogenic or differentiation-related stimuli and are most frequently (although not invariably) associated with pro-survival activity (19, 20). In fact, there is evidence that the relative outputs of the JNK and p42/44 MAPK cascades determine whether a cell lives or dies in response to a noxious stimulus (e.g., growth factor deprivation; Ref. 21). p42/44 MAPK lies downstream of a signaling pathway consisting of PKC, Raf-1, and MEK1 (22). Investigation of the functional role of p42/44 MAPK in cell death decisions, as well as other biological processes, has been greatly facilitated by the development of pharmacological MEK inhibitors, including PD98059 (23), U0126 (24), and SL327 (25). Recently, Seybolt-Leopold et al. (26) described a novel MEK inhibitor, PD184352, which is able to block MAPK activation and to inhibit the in vivo growth of colon tumor cells in mice. Aside from their intrinsic antitumor activity, MEK inhibitors may also have a role as potentializers of established chemotherapeutic drug action (27).

The relationship between UCN-01 actions and activity of the
MAPK pathway is poorly understood. Given the fact that UCN-01 can function as a PKC inhibitor (1) and that it has been shown to mimic some of the actions of the PKC down-regulator bryostatin 1 as well as the kinase inhibitor staurosporine (25), the possibility that UCN-01 might block the downstream PKC targets MEK1/2 and MAPK appeared plausible. To address this issue, we have examined the apoptotic actions of UCN-01 in relation to its effects on the MEK/MAPK cascade. Contrary to expectations, exposure of multiple myeloid and lymphoid cell lines to submicromolar concentrations of UCN-01 potentiated, rather than reduced, MAPK phosphorylation/activation. Moreover, interference with this process by several pharmacological MEK inhibitors, including PD98059, U0126, and PD184352, resulted in a highly synergistic enhancement of mitochondrial damage, caspase activation, and apoptosis in these cells. Together, these findings suggest that exposure of human leukemia cells to UCN-01 elicits a cytotoxic/protective MAPK response and raise the possibility that combining this agent with pharmacological MEK inhibitors may effectively lower the apoptotic threshold.

MATERIALS AND METHODS

Cells. U937, HL-60, Jurkat, CCRF-CEM, and Raji cells are human histiocytic lymphoma, acute promyelocytic leukemia, acute T-cell leukemia, acute lymphoblastic leukemia, and Burkitt lymphoma cell lines, respectively. All of the cells were derived by the American Type Culture Collection and maintained in RPMI 1640 medium containing 10% FBS, 200 units/ml penicillin, 200 µg/ml streptomycin, minimal essential vitamins, sodium pyruvate, and glutamine, as reported previously (28). U937/p21AS and U937/pREP4 cells were obtained by stable transfection of cells with plasmids containing anti-sense-oriented p21 cDNA or an empty vector (pREP4), and clones were selected with hygromycin (29).

Drugs and Reagents. Selective MEK inhibitors (PD98059 and U0126), selective PKC inhibitors (GF 109203X or GFX I and safingol), and specific inhibitors of p38 MAPK (SB203580) were supplied by Calbiochem (San Diego, CA) as powder. The MEK inhibitor PD184352 was kindly provided by Dr. Judith Sebolt-Leopold (Warner Lambert/Parke-Davis Co., Ann Arbor, MI). Materials were dissolved in sterile DMSO and stored frozen under light-protected conditions at −20°C. UCN-01 is kindly provided by Dr. Edward Sausville (Developmental Therapeutics Program/Cancer Treatment and Evaluation Program (CTEP), National Cancer Institute). It was dissolved in DMSO at a stock concentration of 1 mM, stored at −20°C, and subsequently diluted with serum-free RPMI medium before use. Caffeine (Alexis Co., San Diego, CA) was dissolved in chloroform and stored at −20°C. In all of the experiments, the final concentration of DMSO or chloroform did not exceed 0.1%. Caspase inhibitor (Z-VAD-fmk) and caspase 8 inhibitor (Z-IETD-fmk) were purchased from Enzyme System Products (Livermore, CA), dissolved in DMSO, and stored at 4°C. Cycloheximide was purchased from Sigma Chemical Co. (St. Louis, MO), stored frozen in DMSO, and diluted in RPMI 1640 medium before use.

Experimental Format. All of the experiments were performed using logarithmically growing cells (3–5 × 10⁶ cells/ml). Cell suspensions were placed in sterile 25 cm² T-flasks (Corning, Corning, NY) and incubated with MEK or PKC inhibitors for 30 min at 37°C. At the end of this period, UCN-01 (or in some cases, caffeine) was added to the suspension, and the plates were placed in 37°C/5% CO₂ incubator at various intervals, generally 18 h. In some studies, the p38 MAP kinase inhibitor SB203580 was added concurrently with MEK inhibitors. After drug treatment, cells were harvested and subjected to further analysis as described below.

Analysis of Apoptosis. The extent of apoptosis was evaluated by assessment of Wright-Giemsa-stained preparation under light microscopy and scoring at least 500 cells (28). To confirm the results of morphological analysis, in some cases cells were also evaluated by TUNEL staining (30) and assessment of sub-G₁ lymphoblastic DNA fragmentation of total DNA. DNA fragmentation was analyzed by 1.8% agarose gel electrophoresis as described previously (31). For TUNEL staining, cytocide/protective treatments were ob-}

Downloaded from cancerres.aacrjournals.org on May 30, 2017. © 2001 American Association for Cancer Research.
rabbit polyclonal; Santa Cruz Biotechnology Inc.); antihuman/mouse XIAP (1:500; rabbit polyclonal; R&D System, Minneapolis, MN); anti-caspase-3 (1:1000; rabbit polyclonal; PharMingen); cleaved-caspase-3 (M 17,000) antibody (1:1000; rabbit polyclonal; Cell Signaling Technology); anti-caspase-9 (1:1000; rabbit polyclonal; PharMingen); anti-PARP (1:2500; mouse monoclonal; Calbiochem); and cleaved PARP (M 89,000) antibody (1:1000; rabbit polyclonal; Cell Signaling Technology).

Immunoprecipitation was performed to determine the extent of cdc25C activation (32). Briefly, 2 × 105 cells were lysed in RIPA buffer (1% NP40, 0.5% Na deoxycholate, 1 mM phenylmethylsulfonyl fluoride, 1 mM Na vanadate, 5 µg/ml chymostatin, leupeptin, aprotinin, and soybean trypsin inhibitor, and 0.1% SDS in PBS) by sonrying approximately 20 times with a 23-gauge needle. Protein samples were centrifuged at 12,800 × g for 30 min and quantified. Two-hundred µg of protein/condition were incubated under continuous shaking with 1 µg of anti-cdc25C (mouse monoclonal; PharMingen) overnight at 4°C. Twenty µl/condition of Dynabeads (goat antimouse IgG; Dynal, Oslo, Norway) were added and incubated for an additional 4 h. After washing three times with RIPA buffer, the bead-bound protein was eluted by vortexing and boiling in 20 µl of 1 × sample buffer. The samples were separated by 12% SDS-PAGE and subjected to immunoblot analysis as described above. Anti-14-3-3β (rabbit polyclonal; Santa Cruz Biotechnology Inc.) was used as primary antibody at a dilution of 1:200.

Analysis of Cytosolic Cytochrome c. Cells (2 × 105) were washed in PBS and lysed by incubating for 30 s in lysis buffer (75 mM NaCl, 8 mM NaHPO4, 1 mM NaH2PO4, 1 mM EDTA, and 350 µg/ml digitonin). The lysates were centrifuged at 12,000 × g for 1 min, and the supernatant was collected and added to an equal volume of 2 × sample buffer. The protein samples were quantified, separated by 15% SDS-PAGE, and subjected to immunoblot analysis as described above. Anticytochrome c (mouse monoclonal; PharMingen) was used as primary antibody at a dilution of 1:500.

Cdk1/edc2 Kinase Assay. Cdk1/edc2 Kinase Assay Kit (Upstate Biotechnology) was used to determine the activity of cdk1/edc2 kinase according to the manufacturer’s instructions. Briefly, 2 × 105 cells were lysed in RIPA buffer by sonication. Protein samples were centrifuged at 12,800 × g for 30 min and quantified. Fifty µg of protein/condition were incubated with 400 µg/ml histone H1, 2 µCi of [γ-32P]ATP, and 1:5 inhibitor cocktail in assay dilution buffer (total volume, 50 µl) at 30°C for 20 min. A 25-µl aliquot of reaction mixture was transferred onto P81 paper. After washing three times with 0.75% phosphoric acid and once with acetone, cpn of [γ-32P] incorporated into histone H1 was monitored using TRI-CARB 2100TR Liquid Scintillation Analyzer (Packard Instrument Co., Downers Grove, IL). In some cases, 10 µl of 2 × sample buffer was added to 10 µl of the reaction mixture and boiled for 5 min. [γ-32P]Histone H1 was separated by 12% SDS-PAGE and visualized by exposure of the dried gels to X-ray film (KODAK) at −80°C for 1 h.

Clonogenic Assay and Cell Proliferation Assays. Colony formation after drug treatment was evaluated using a soft agar cloning assay as described previously (33). Briefly, cells were washed three times with serum-free RPMI medium. Subsequently, 500 cells/well were mixed with RPMI medium containing 20% FBS and 0.3% agar and plated on 12-well plates (three wells/condition). The plates were then transferred to a 37°C/5% CO2, fully humidified incubator. After 10 days of incubation, colonies, consisting of groups of >50 cells, were scored using an Olympus Model CK inverted microscope, and colony formation for each condition was calculated in relation to values obtained for untreated control cells. For cell viability assays, CellTiter 96 AQueous One Solution (Promega, Madison, WI) was used according to the manufacturer’s instructions, and the absorbance at 490 nm was recorded using a 96-well plate reader (Molecular Devices, Sunnyvale, CA).

Normal Peripheral Blood Mononuclear Cells. Peripheral blood was obtained with informed consent from normal volunteers, diluted 1:3 with RPMI 1640 medium, and layered over a cushion of 10 ml of Ficoll-Hypaque (specific gravity, 1.077; Sigma Chemical Co.) in sterile 50-ml plastic centrifuge tubes. These studies have been approved by the Human Investigations Committee of Virginia Commonwealth University. After centrifugation for 40 min at 400 × g at room temperature, the interface layer, consisting of mononuclear cells, was extracted with a sterile Pasteur pipette and diluted in fresh RPMI medium. The cells were washed ×2 in medium and resuspended in RPMI 1640 medium containing 10% FCS in 25-cm² tissue culture flasks at a cell density of 106 cells/ml. Various concentrations of UCN-01 ± PD 184352 were added to the flasks, after which they were placed in the incubator for 24 h. At the end of this period, cytospin preparations were obtained and stained with Wright-Giemsa, and the cells were scored under light microscopy for the typical morphological features of apoptosis.

Statistical Analysis. For morphological assessment of apoptotic cells, cell cycle analysis, S-phase content, cdk1/edc2 kinase assay, analysis of ΔΨm, and clonogenic and cell proliferation assays, experiments were repeated at least three times. Values represent the means ± SD for at least three separate experiments performed in triplicate. The significance of differences between experimental variables was determined using the Student t test.

RESULTS

The effects of combined exposure of human mononuclear leukemia cells (U937) to UCN-01 and the MEK inhibitor PD184352 were first examined in relation to MAPK activation and apoptosis (Fig. 1). Unexpectedly, incubation with UCN-01 (150 nM) induced phosphorylation (activation) of MAPK by 2 h, and this effect persisted over the ensuing 18 h (Fig. 1A). Coincubation of U937 cells with PD184352 (10 µM) attenuated induction of phospho-MAPK at 2 h, and inhibition of MAPK activation was essentially complete after 18 h. To determine what impact this phenomenon had on cell fate, the extent of apoptosis was monitored in cells exposed to each agent individually and in combination. Whereas exposure to PD184352 or
lysed, and DNA was extracted, separated by agarose gel electrophoresis, and stained with UCN-01. The increase in cell death (i.e., apoptosis in each case), combined treatment resulted in a dramatic decrease in the number of cells exhibiting loss of the mitochondrial membrane potential (△ψm), an increase in oligonucleosomal DNA fragmentation, PARP degradation, and release of cytochrome c into the cytoplasm (Fig. 1). Together, these findings indicate that coadministration of the MEK inhibitor PD184352 blocks MAPK activation and dramatically increases apoptosis in U937 cells exposed to a marginally toxic concentration of UCN-01.

To determine whether these findings could be extended to other known MEK inhibitors, U937 cells were incubated for 24 h with 200 nM UCN-01 either alone or in combination with PD98059 (50 μM), an aminoflavone that was among the earliest of the MEK inhibitors to be investigated (23), and U0126 (20 μM), the affinity of which for the CDK ATP-binding site is significantly greater than that of PD98059 (24). As noted in the case of PD184352, coadministration of minimally toxic concentrations of PD98059 or U0126 with 200 nM UCN-01 resulted in a marked potentiation of cell death, manifested by an increase in the morphological features of apoptosis (Fig. 3, A and C), PARP degradation, and release of cytochrome c into the cytoplasm (Fig. 3, B and D). These findings demonstrated that multiple pharmacological MEK inhibitors are capable of substantially increasing the lethal actions of UCN-01 toward U937 cells.

To establish whether the enhanced lethality of MEK inhibitors and UCN-01 was restricted to U937 cells or, instead, might be generalized to include other leukemia cell types, the effects of combined exposure to UCN-01 and PD184352 were examined in several additional leukemia cell lines (Fig. 4). Because the sensitivity of these cells to UCN-01 differed somewhat from that of U937 cells, slightly higher UCN-01 concentrations (e.g., 150–300 nM) were used in some cases. On the basis of standard morphological criteria as well as evidence of PARP degradation, it can be seen that combined treatment with UCN-01 and PD184352, administered at concentrations that were marginally toxic by themselves, resulted in a dramatic increase in cell death in HL-60 promyelocytic leukemia cells, T-lymphoblastic CCRF-CEM and Jurkat cells, and B-lymphoblastic lymphoma Raji cells (Fig. 4, A and B). Qualitatively similar results were obtained when PD98059 and U0126 were used (data not shown). As in the case of U937 cells, UCN-01 treatment resulted in a substantial increase in MAPK activation in HL-60, CCRF-CEM, and in Jurkat cells (Fig. 4C); moreover, this effect was blocked by PD184352 (5 μM). Thus, combined treatment with UCN-01 and MEK inhibitors prevented MAPK activation and produced a dramatic increase in apoptosis in a variety of myeloid and lymphoid cell lines.

To investigate the hierarchy of events accompanying apoptosis induced by these agents, U937 cells were exposed to the combination of UCN-01 (150 nM) in conjunction with 10 μM PD184352 in the...
presence or absence of the broad caspase inhibitor ZVAD-fmk as well as the caspase-8 inhibitor IETD-fmk, after which cytochrome c release, loss of \( \Delta \psi_{\text{mit}} \), caspase activation, PARP degradation, and apoptosis were monitored (Fig. 5). Whereas ZVAD-fmk blocked induction of apoptosis and loss of \( \Delta \psi_{\text{mit}} \) in U937 cells exposed to UCN-01 and PD 184352, IETD was ineffective (Fig. 5, A and B). Similarly, ZVAD, but not IETD (20 \( \mu \text{M} \) each), prevented procaspase-3 cleavage and PARP degradation (Fig. 5C). In contrast, ZVAD, like IETD, failed to reduce cytochrome c release in UCN-01/PD184352-treated cells. These findings are compatible with the notion that cytochrome c release represents the primary event in UCN-01/PD184352-induced apoptosis, whereas the loss of mitochondrial membrane potential is a secondary process that stems from caspase activation. They also indicate that UCN-01/PD-induced apoptosis proceeds through a caspase-8-independent pathway.

Because UCN-01 can act as an inhibitor of PKC (1), attempts were made to determine whether this action might be responsible for or contribute to pro-apoptotic interactions with UCN-01. To this end, U937 cells were exposed for 18 h to 10 \( \mu \text{M} \) PD 184352 alone or in combination with two known PKC inhibitors, i.e., GFX (1 \( \mu \text{M} \)) or safingol (2 \( \mu \text{M} \); Table 1). In separate studies, these drug concentrations were found to block PMA-mediated MAPK phosphorylation in U937 cells (data not shown). In marked contrast to interactions with UCN-01, coadministration of PD 184352 with either GFX or safingol produced relatively minor or no changes in apoptosis or loss of \( \Delta \psi_{\text{mit}} \), arguing against the possibility that synergism between MEK inhibitors and UCN-01 solely involves PKC inhibition.

Interactions between PD184352 and UCN-01 were then examined in relation to cell cycle events (Fig. 6). Administration of PD184352 by itself for 18 h had little effect on the cell cycle distribution of U937 cells, whereas UCN-01 (150 \( \text{nM} \)) primarily depleted the G2 M population. Examination of BrdUrd incorporation, reflecting DNA synthesis, at 12 and 18 h of drug exposure revealed a modest decline in the number of BrdUrd-positive cells after PD184352 treatment, but no effect after incubation with UCN-01 (Fig. 6B). However, a very substantial decline in BrdUrd-positive cells was noted 12 h and

Table 1 Effects of combining PD184352 with the PKC inhibitors GFX or safingol on apoptosis and loss of \( \Delta \psi_{\text{mit}} \) in U937 cells

<table>
<thead>
<tr>
<th>Drug/Concentration</th>
<th>Apoptotic (%)</th>
<th>&quot;Low&quot; ( \Delta \psi_{\text{mit}} ) (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Control</td>
<td>1.5 ± 0.3</td>
<td>11.7 ± 1.3</td>
</tr>
<tr>
<td>GFX (1 ( \mu \text{M} ))</td>
<td>1.9 ± 0.2</td>
<td>13.2 ± 0.6</td>
</tr>
<tr>
<td>PD184352 (10 ( \mu \text{M} ))</td>
<td>2.1 ± 0.1</td>
<td>14.7 ± 1.0</td>
</tr>
<tr>
<td>GFX + PD</td>
<td>2.2 ± 0.2</td>
<td>15.7 ± 1.7</td>
</tr>
<tr>
<td>Control</td>
<td>1.5 ± 0.2</td>
<td>10.5 ± 0.2</td>
</tr>
<tr>
<td>Safingol (2 ( \mu \text{M} ))</td>
<td>1.9 ± 0.2</td>
<td>13.6 ± 0.8</td>
</tr>
<tr>
<td>PD184352 (10 ( \mu \text{M} ))</td>
<td>1.8 ± 0.1</td>
<td>12.1 ± 0.2</td>
</tr>
<tr>
<td>Safingol + PD</td>
<td>2.4 ± 0.1</td>
<td>16.4 ± 1.1</td>
</tr>
</tbody>
</table>

Fig. 5. U937 cells were exposed to PD184352 (PD; 10 \( \mu \text{M} \)) + UCN-01 (UCN; 150 \( \text{nM} \)) for 10 h in the presence or absence of the broad caspase inhibitor ZVAD-fmk (20 \( \mu \text{M} \)) or the caspase-8 inhibitor IETD-fmk (20 \( \mu \text{M} \)). At the end of this period, cytospin preparations were monitored for apoptosis by morphological examination of Wright Giemsa-stained specimens (A) or the percentage of cells displaying a reduction in \( \Delta \psi_{\text{mit}} \) (B) determined by flow cytometry as described in "Materials and Methods." Values represent the means ± SD for three separate experiments performed in triplicate.
were lysed, and the proteins were separated by SDS-PAGE. Proteins were then probed with an antibody directed against phospho(tyrosine-15)-p34\(^{cdcl2}\). Each lane was loaded with 30 \(\mu\)g of protein. Blots were subsequently stripped and reprobed for actin to ensure equivalent loading and transfer of protein. Alternatively, proteins were immunoprecipitated with an antibody directed against cdc25C and subsequently subjected to Western analysis with an antibody directed against the 14-3-3 protein. Lastly, a 10-kDa reaction mixture of cdk1/cdc2 kinase assay was used to separate \(^{32}\)P-labeled histone H1 by 12% SDS-PAGE (C, bottom two panels). D, cells were treated as above for 18 h, after which cdk1/cdc2 activity (expressed as cpm of \(^{32}\)P incorporated into histone H1) was determined by cdk1/cdc2 kinase assay as described in “Materials and Methods.” Values represent the means ± SD for three separate experiments. *, significantly greater than values for UCN-01 alone; \(P \leq 0.05\).

Fig. 7. A, cells were treated with PD 184352 (PD; 10 \(\mu\)M) or caffeine (C, 2 mM) for 18 h, after which the percentage of cells in G0/G1, G2/M, S-phase, or the subdiploid fraction (Ap) was determined as described in “Materials and Methods.” B, alternatively, cells were treated with the same agents for 12 h or 18 h, after which the percentage of BrdUrd FITC-positive (S-phase) cells was determined by flow cytometry as described in “Materials and Methods.” Values represent the means ± SD determined by cdk1/cdc2 kinase assay as described in “Materials and Methods.” C, cells were treated as above for 18 h, after which they were lysed, and the proteins were separated by SDS-PAGE. Proteins were then probed with an antibody directed against phospho(serine-15)-p34\(^{cdcl2}\). Each lane was loaded with 30 \(\mu\)g of protein. Blots were subsequently stripped and reprobed for actin to ensure equivalent loading and transfer of protein. Alternatively, cells were exposed to the same agents for 12 h or 18 h, after which the percentage of apoptotic cells was determined by morphological examination as described previously. Values represent the means ± SD for three separate experiments performed in triplicate. *, significantly greater than values for control; \(P \leq 0.05\); **, \(P \leq 0.02\). C, cells were treated as above for 18 h, after which they were lysed, and the proteins were separated by SDS-PAGE. Proteins were then probed with an antibody directed against cdc25C and subsequently subjected to Western analysis with an antibody directed against the 14-3-3 protein. Lastly, a 10-kDa reaction mixture of cdk1/cdc2 kinase assay was used to separate \(^{32}\)P-labeled histone H1 by 12% SDS-PAGE (C, bottom two panels). D, cells were treated as above for 18 h, after which Western analysis was performed to assess expression of p21CIP1, p27KIP1, and CREB as described in “Materials and Methods.” Each lane was loaded with 30 \(\mu\)g of protein. Blots were stripped and reprobed for expression of tubulin to ensure equivalent loading and transfer of protein. Two additional studies yielded comparable results. D, U937 cells stably expressing an empty vector (pREP4) and a p21CIP1 antisense construct (p21AS) were exposed to UCN-01 (UCN; 150 \(\mu\)M) or PD 184352 (PD; 10 \(\mu\)M) for 18 h, after which Western analysis was performed to assess expression of p21, p27, and phospho-CREB as described in “Materials and Methods.”

INDUCTION OF APOPTOSIS BY UCN-01 AND MEK INHIBITORS

Fig. 6. A, U937 cells were exposed to UCN-01 (UCN; 150 \(\mu\)M) or PD 184352 (PD; 10 \(\mu\)M) for 12 h and/or 18 h, after which the percentage of cells in G0/G1, G2/M, S-phase, or the subdiploid fraction (Ap) was determined as described in “Materials and Methods.” B, alternatively, cells were exposed to the same agents for 12 h or 18 h, after which the percentage of BrdUrd FITC-positive (S-phase) cells was determined by flow cytometry as described in “Materials and Methods.” Values represent the means ± SD for three separate experiments performed in triplicate. *, significantly greater than values for control; \(P \leq 0.05\); **, \(P \leq 0.02\). C, cells were treated as above for 18 h, after which they were lysed, and the proteins were separated by SDS-PAGE. Proteins were then probed with an antibody directed against phospho(serine-15)-p34\(^{cdcl2}\). Each lane was loaded with 30 \(\mu\)g of protein. Blots were subsequently stripped and reprobed for actin to ensure equivalent loading and transfer of protein. Alternatively, cells were exposed to the same agents for 12 h or 18 h, after which the percentage of apoptotic cells was determined by morphological examination as described previously. Values represent the means ± SD for three separate experiments performed in triplicate. *, significantly greater than values for control; \(P \leq 0.05\); **, \(P \leq 0.02\).
Coadministration of UCN-01 and PD184352 did not result in a significant change in expression of Bcl-2, Bcl-xL, Bax, or XIAP. Similar results were observed in cells exposed to the combination of UCN-01 and PD98059 (data not shown). In addition, separation of proteins on a 15-cm, 12% SDS-PAGE gel, which permitted visualization of a slowly migrating, putatively phosphorylated Bcl-2 species (Fig. 7C, second panel from top), revealed no significant change after exposure of cells to PD184352 in combination with UCN-01. These observations argue against the possibility that potentiation of UCN-01-induced apoptosis by MEK inhibitors stemmed from increased expression of Bax or diminished expression of the antiapoptotic proteins Bcl-2, Bcl-xL, or XIAP.

Finally, the impact of combined treatment of U937 cells with UCN-01 and PD184352 was examined in relation to effects on clonogenic survival (Fig. 9). UCN-01 (150 nM; 18 h) by itself had a very modest effect on colony formation, whereas PD184352 (10 μM; 18 h) administered alone reduced clonogenic survival by ~40%. However, combined treatment with both agents resulted in a substantial reduction in clonogenicity (e.g., to ~10% of control values; Fig. 9A). Furthermore, median dose effect analysis (39) was used to character-

Fig. 8. A, U937 cells were exposed to UCN-01 (UCN; 150 nM) ± PD184352 (PD; 10 μM) for 18 h, after which they were lysed, and the lysates were separated by SDS-PAGE and probed with antibodies directed against phospho-p38 MAPK, phospho-JNK, total JNK, MKP1, and MKP3. B, cells were exposed to PD184352 and UCN-01 as above for 18 h in the presence or absence of the p38 MAPK inhibitor SB203580 (10 μM), after which the percentage of cells exhibiting the morphological features of apoptosis or reduction in ΔΨm, reflected by a diminished uptake of DiOC6, was determined as described previously. Values represent the means ± SD for three separate experiments performed in triplicate. **, significantly less than values for UCN + PD without SB203580; P = 0.02. C, cells were treated as above, after which levels of expression of Bcl-2, Bax, Bcl-xL, or XIAP were determined by Western analysis as described in “Materials and Methods.” Alternatively, proteins were separated by running a 15-cm 12% SDS-PAGE gel, which permitted detection of a putatively phosphorylated, slowly migrating Bcl-2 species (designated phospho-Bcl-2). For A and C, each lane was loaded with 30 μg of protein. Blots were stripped and reprobed for actin to ensure equivalent loading and transfer of protein. In each case, two additional studies yielded comparable results.

dysregulated in the antisense line, these and the preceding findings (Fig. 7C) argue against the possibility that potentiation of UCN-01-related apoptosis by MEK/MAPK inhibitors involves impaired induction of the downstream MAPK target p21CIP1.

To assess the influence of MEK inhibitors and UCN-01 on other MAPK pathways, the effects of these agents were examined in relation to JNK and p38 phosphorylation (Fig. 8). In contrast to the increase in expression of phospho-MAPK, UCN-01, either alone or in combination with PD184352, did not noticeably induce JNK phosphorylation in U937 cells (Fig. 8A). Similar results were obtained with PD98059 (data not shown). In separate studies (38) involving U937 cell transfectants, stable expression of a dominant-negative c-Jun transactivation domain-deficient mutant (TAM67) did not attenuate UCN-01-induced apoptosis by MEK inhibitors stemmed from increased expression of Bcl-2, Bcl-xL, or XIAP.

Fig. 9. A, cells were exposed to PD184352 (5 μM) ± UCN-01 (100 nM) for 18 h, after which cells were washed free of drug and plated in soft agar as described in the text. After 12 days of incubation, colonies, consisting of groups of ≥50 cells, were scored, and colony formation for each condition was expressed relative to untreated control cells.

Values represent the means ± SD for three separate experiments. B, U937 cells were exposed to a range of PD184352 (e.g., 3.75–10 μM) and UCN-01 (e.g., 75–200 nM) concentrations alone and in combination at fixed ratio (e.g., 50:1) for 18 h. At the end of this period, colony formation was determined for each condition as above. Alternatively, cell viability was determined using the cell titer 96 reagent as described in “Materials and Methods.” In each case, the fraction affected values were determined by comparing results with those of untreated controls, and median dose-effect analysis was used to characterize the nature of the interaction between UCN-01 and PD184352 using a commercially available program (Calcusyn; Biosoft).

Values obtained for clonogenic assays; ▼, values obtained for viability assays. Combination index values less than 1.0 denote a synergistic interaction. Two additional studies yielded equivalent results. C, normal peripheral blood mononuclear cells were exposed to 150 nM UCN-01 ± 10 μM PD184352 for 18 h, after which the percentage of apoptotic cells was determined by morphological examination as described previously. Values represent the means ± SD for triplicate determination; a second independent study yielded equivalent results.
ize interactions between these agents, administered at a fixed ratio (e.g., PD/UCN-01, 50:1), over a range of UCN-01 concentrations (e.g., 75–200 nM; Fig. 9B). Combination index values for the drug combination, using either a reduction in clonogenicity (●) or loss of viability by MTS assay (▲) as end points, were considerably less than 1.0 (Fig. 9B), corresponding to a highly synergistic interaction. These findings indicate that enhanced apoptosis in cells exposed to UCN-01 in combination with a MEK/MAPK inhibitor is accompanied by a significant reduction in leukemic cell viability and self-renewal capacity. Finally, parallel studies were carried out using normal peripheral blood mononuclear cells. Exposure of such cells for 24 h to 150 nM UCN-01 ± 10 μM PD184352 did not result in a significant increase in apoptosis for any of the conditions (e.g., <5% increases versus controls; P ≥ 0.05 for each condition). Similar results were observed in cells exposed to the combination of UCN-01 and PD98059 or UO126 (data not shown). These findings raise the possibility that coadministration of UCN-01 with MEK/MAPK inhibitors may not represent a potent apoptotic stimulus in at least some normal hematopoietic cells.

DISCUSSION

The present study demonstrates that marginally toxic concentrations of the PKC inhibitor and checkpoint abrogator UCN-01 induce activation of the MEK/MAPK pathway in human leukemia cells. Furthermore, interference with this process, e.g., by coadministration of specific MEK inhibitors, potently triggers mitochondrial damage and apoptosis in multiple myeloid and lymphoid leukemia cell types. PKC inhibitors are known to be among the most effective inducers of apoptosis in both hematopoietic and nonhematopoietic cells (40, 41). However, although UCN-01 was originally developed as a specific PKC inhibitor (1), there is evidence that interruption of the PKC pathway, e.g., by UCN-01 (13) or related agents (42), may not be primarily responsible for or sufficient to induce apoptosis in hematopoietic cells. The observations that the PKC inhibitors safingol and GFX failed to interact synergistically with MEK/MAPK inhibitors (Table 1) are in accord with this view and suggest that the antileukemic synergism between UCN-01 and MEK/MAPK inhibitors involves factors other than or in addition to disruption of the PKC pathway.

The finding that structurally dissimilar MEK1/2 inhibitors, which exhibit different mechanisms of action, interact synergistically with UCN-01 to induce apoptosis strongly implicates interference with MAPK activation in the lethality of this drug combination. Whereas PD98059, U0126, and PD184352 oppose Raf-1-induced activation of MEK1/2 (23, 43), U0126 and PD184352 are also potent inhibitors of the MEK1/2 catalytic site (24). However, each of these agents blocked UCN-01-mediated activation of MAPK and promoted mitochondrial damage and cell death. Although MAPK activation has generally been associated with cytotoxic protective functions (44), it is important to note that disruption of this pathway in U937 cells was not, by itself, a potent inducer of cell death. Such findings are consistent with previous studies demonstrating that interruption of the MAPK cascade by pharmacological or other means potentiates apoptosis in cells exposed to other environmental stresses, e.g., growth factor deprivation (21) or exposure to DNA-damaging agents (27, 45). Collectively, such findings suggest that activation of the MAPK pathway may not be essential for cell survival per se, but that it plays a critical role in protecting the cell from a variety of noxious stimuli.

Induction of apoptosis, particularly by chemotherapeutic drugs, has been linked to mitochondrial damage, including loss of the mitochondrial membrane potential or release of pro-apoptotic proteins from the mitochondrial intermembrane space, particularly cytochrome c (46). There is some controversy regarding whether or not these proteins represent the initiating apoptotic event; e.g., the induction of apoptosis in the absence of cytochrome c release has been described (47), suggesting a critical role for loss of Δψm in cell death decisions. On the other hand, cytochrome c release often precedes loss of Δψm (48), and a dissociation between apoptotic events and decreases in Δψm has been reported in human leukemia cells such as HL-60 and U937 (49). The present findings strongly suggest that cytochrome c release represents an upstream event in cells induced to undergo apoptosis by UCN-01 and MEK inhibitors; e.g., whereas the broad caspase inhibitor ZVAD-fmk substantially blocked UCN-01/PD184352-induced apoptosis, caspase activation, and mitochondrial discharge, cytochrome c release was unperturbed. Cytochrome c release can also be triggered by the Fas/APO-related pathway through activation of procaspase-8 and cleavage/activation of the pro-apoptotic effector, Bid (50). However, the inability of the procaspase-8 inhibitor IETD to oppose apoptosis or cytochrome c release argues against a role for the receptor-mediated cell death pathway in the lethal actions of UCN-01/MEK inhibitor combination.

Recent studies (51) involving malignant lymphoid cells have raised the possibility that kinase inhibitors such as UCN-01 may promote apoptosis by modulating expression of Bcl-2 and related family members or by inducing post-translational modifications (e.g., phosphorylation) in these proteins that interfere with antiapoptotic function. Analogously, PD98059 has been shown to block Bcl-2 phosphorylation and, in so doing, to lower the threshold for growth factor deprivation-induced apoptosis (52). However, we were unable to demonstrate alterations in the expression or in the mobility of Bcl-2 on PAGE electrophoresis, a phenomenon that generally (although not invariably) accompanies perturbations in phosphorylation state (53), nor were changes in levels of expression of several other apoptotic regulatory proteins observed. The complexity of apoptosis regulation is underscored by the numerous events that can modulate this process, including procaspase-9 phosphorylation (54), apaf-1 oligomerization (55), and the release of newly described mitochondrial proteins (e.g., SMAC/Diablo) that antagonize the actions of inhibitors of apoptosis (56). Consequently, the possibility that one or more of these mechanisms operates to enhance apoptosis in leukemic cells exposed to UCN-01 in conjunction with MEK inhibitors cannot be excluded. Studies addressing these issues are currently in progress.

Given the present results, it is tempting to speculate that the lethality of the combination of UCN-01 and MEK inhibitors involves, at least to some extent, interactions at the level of CDK1 (p34cdc2). Dysregulation of this CDK (e.g., unscheduled activation) has been identified as a particularly potent inducer of cell death (57) and has been associated with the “mitotic catastrophe,” which resembles (although is not identical to) classic apoptosis (58). It is unlikely to be coincidental that the ability of UCN-01, a well-documented inhibitor of Chk1 (2), to induce apoptosis in leukemic cells has been attributed previously (13) to dephosphorylation/activation of CDKs, including p34cdc2. It may also be significant that MEK/MAPK activation has been implicated in induction of p34cdc2 and cell cycle progression through G2/M (40). Consequently, the notion that cross-talk exists between these pathways appears quite plausible. One possible explanation for the present findings is that the cytoprotective actions of MAPK prevent cells progressing through G2/M from undergoing apoptosis. Conversely, interference with such putative antiapoptotic actions (e.g., by pharmacological MEK/MAPK inhibitors) may permit the pro-apoptotic activity of p34cdc2 to proceed unopposed. This concept is supported by the observation that caffeine, which acts upstream of Chk1 at the level of ATM (59), interacted with MEK/MAPK inhibitors in a manner similar to that of UCN-01. Interference with Chk1 activity opposes cdc25C phosphorylation, sequestration by 14-3-3 proteins, and subsequent proteasomal degradation, thereby
allowing this phosphatase to dephosphorylate and activate p34cdc2 (3). Thus, in the present studies, coadministration of caffeine, like UCN-01, with PD184352 resulted in reduced binding of the cdc25C phosphatase to 14-3-3 proteins, dephosphorylation of p34cdc2, and a marked increase in lethality. Collectively, these findings suggest that the combination of p34cdc2 activation with disruption of the MAPK cascade represents a potent apoptotic stimulus, at least in the case of malignant hematopoietic cells.

The possibility that other downstream MAPK effectors contribute to this phenomenon cannot be ruled out, particularly in view of the reduced phosphorylation of CREB noted in UCN-01/PD184352-treated cells. CREB has been identified recently (36, 60) as a cytoprotective target of the Raf→MAPK→Rsk cascade, and it seems plausible that interference with phosphorylation/activation of this transcription factor (e.g., by PD184352) contributed to the observed potentiation of apoptosis. In addition, cross-talk between cytoprotective and stress-related MAPK modules has been described (61), and it is possible that such interactions might contribute to the lethality of the UCN-01/PD184352 combination. In fact, the observations that inhibition of UCN-01-induced MAPK activation by PD184352 was associated with a reciprocal increase in p38 MAPK induction and that coadministration of the p38 MAPK inhibitor SB203580 partially protected cells from apoptosis induced by UCN-01/PD184352 raise the possibility that the p38 MAPK cascade could be involved, at least to some extent, in potentiation of cell death by this drug combination. However, given recent evidence (62) that SB203580 inhibits kinases other than p38 MAPK and the finding that protection from apoptosis by SB203580 was incomplete, it seems highly likely that other factors are involved in the lethal effects of this drug combination. Lastly, the possibility that MEK inhibitors specifically act by interfering with induction of p21^{CIP1}, a known MAPK downstream target (63), and p21^{CIP1} antisense-expressing cells, which already exhibit dysregulation of this CDKI, displayed enhanced susceptibility to the UCN-01/PD184352 combination. Nevertheless, these findings remain compatible with a cytoprotective role for basal p21^{CIP1} expression, a phenomenon that has been described previously (64).

In summary, the present studies demonstrate that the kinase inhibitor and checkpoint antagonist UCN-01 unexpectedly activates MAPK in human leukemia cells and that interference with this process by multiple pharmacological MEK/MAPK inhibitors leads to a marked potentiation of mitochondrial injury (e.g., cytochrome c release), caspase activation, and apoptosis. Moreover, these events occur in a variety of myeloid and lymphoid leukemia cell types, indicating that this phenomenon is not lineage-specific. Finally, enhanced apoptosis in these cells is associated with perturbations in several signaling and cell cycle regulatory pathways, including dephosphorylation of p34^{cdc2} and CREB, as well as activation of p38 MAPK. Significantly, such observations raise the possibility that interruption of multiple signaling pathways (e.g., by pharmacological kinase inhibitors) may provide a particularly potent apoptotic stimulus, at least in malignant hematopoietic cells. Aside from providing insights into factors that regulate the lethal actions of UCN-01, these findings have potential therapeutic implications; e.g., in humans, levels of free UCN-01 achievable in the plasma and potentially available to tumor cells are limited by extensive binding of this agent to α1-acid glycoprotein (14). It is conceivable that MEK inhibitors, particularly those which, like PD184352, are active in vivo (26), could potentiate the antileukemic activity of pharmacologically relevant concentrations of UCN-01. In this regard, it would be of interest to determine whether synergistic interactions between UCN-01 and MEK/MAPK inhibitors could be extended to other hematological and nonhematological tumor types. Accordingly, studies addressing this question are currently underway.

REFERENCES

INDUCTION OF APOPTOSIS BY UCN-01 AND MEK INHIBITORS


Pharmacological Inhibitors of the Mitogen-activated Protein Kinase (MAPK) Kinase/MAPK Cascade Interact Synergistically with UCN-01 to Induce Mitochondrial Dysfunction and Apoptosis in Human Leukemia Cells


Updated version
Access the most recent version of this article at:
http://cancerres.aacrjournals.org/content/61/13/5106

Cited articles
This article cites 64 articles, 41 of which you can access for free at:
http://cancerres.aacrjournals.org/content/61/13/5106.full.html#ref-list-1

Citing articles
This article has been cited by 55 HighWire-hosted articles. Access the articles at:
http://cancerres.aacrjournals.org/content/61/13/5106.full.html#related-urls

E-mail alerts
Sign up to receive free email-alerts related to this article or journal.

Reprints and Subscriptions
To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org.

Permissions
To request permission to re-use all or part of this article, contact the AACR Publications Department at permissions@aacr.org.